WPI Grants Provost Award to Student Team for Their Work at Nemucore Medical Innovations

WORCESTER, Mass. - May 21, 2014 - PRLog -- Nemucore Medical Innovations, Inc. (NMI), a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted nanomedicines for the treatment of multidrug resistant cancers, announced today that Worcester Polytechnic Institute students Joseph Cacaccio and Eileen Wrabel won WPI’s Provost Award in Biochemistry for their work at NMI.

WPI's Provost Award is granted to one team from each academic major for the research and presentation of their Major Qualifying Project (MQP). Joseph and Eileen’s project was entitled “Development and Analysis of a Novel Nanotherapeutic for the Treatment of Glioblastoma Multiforme.” The team researched and tested potential treatment and targeting options for nanotherapeutics at Nemucore, several options of which are currently undergoing further experimentation.

“We are very proud of Joseph and Eileen for their work on glioblastoma research and for earning such a prestigious award,” explained NMI’s CEO, Timothy Coleman. "Our goal of hosting MQP students from WPI is to teach them think critically and meet the high quality standards of commercial research and development. Joseph and Eileen’s reception of WPI’s Provost Award displays the high standards that these students are able to reach. We are very proud of their work and are excited to work with additional local students in the upcoming school year."

Nemucore is currently continuing Joseph and Eileen’s research and will be hosting two more MQP teams to preform research on glioblastoma and multidrug resistant ovarian cancer therapies this coming school year.

About Nemucore Medical Innovations, Inc.

NMI is dedicated to designing, investigating, developing, and commercializing life-saving novel nanomedicines for the treatment of ovarian cancer and other unmet medical needs. Ultimately, NMI’s products will be part of the personalized medicine revolution occurring in cancer therapies.  Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic.  As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester, Massachusetts. For more information, please visit http://www.nemucore.com.

Forward-looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.